GPCM
IMVT icon

Granite Point Capital Management’s Immunovant IMVT Stock Holding History

Granite Point Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$1.22M – 179
2020
Q2 		$1.22M Buy
50,000
+15,000
+43% +$321K 0.06% 104
2020
Q1 		$545K Sell
35,000
-185,000
-84% -$2.78M 0.31% 63
2019
Q4 		$3.49M Buy
+220,000
New +$2.46M 0.55% 26

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Granite Point Capital Management's IMVT Position: Q3 2020 in Review

Granite Point Capital Management sold out of Immunovant (IMVT) in Q3 2020, closing a stake of 50,000 shares — an estimated $1.22M sold.

Granite Point Capital Management first reported a position in IMVT in Q4 2019 and held it in 3 quarters. The position peaked at $3.49M in Q4 2019. 115 funds tracked by Wall St. Rank hold IMVT as of Q3 2020.

  • Granite Point Capital Management reported no remaining Immunovant position as of Q3 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 50,000 Immunovant shares in Q3 2020, an estimated $1.22M.
  • Granite Point Capital Management first reported a position in Immunovant in Q4 2019 and held it in 3 quarters.
  • Granite Point Capital Management's Immunovant position peaked at $3.49M in Q4 2019.
  • 115 funds tracked by Wall St. Rank held Immunovant as of Q3 2020.

Based on Granite Point Capital Management's 13F filing for Q3 2020, filed 6 Nov 2020.